New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 29, 2014
08:18 EDTIPXLImpax announces FDA performs inspection on Taiwan facility
Impax announced that the FDA performed a general GMP inspection and a Pre-Approval Inspection for RYTARYTM at the company's Taiwan manufacturing facility from July 21 to July 26. At the conclusion of the inspection, the FDA issued a Form 483 with ten inspectional observations. The Taiwan facility was approved for product manufacturing by the FDA in September 2009 and by Taiwan FDA in July 2010. The facility currently manufactures 12 products for distribution in the United States. The FDA did not provide any status or classification to these observations and will wait until they have received and reviewed the company's response to provide this information. The Ccmpany has also not been informed by the FDA of the impact this Form 483 may have on RYTARY's October 9 review date under the Prescription Drug User Fee Act.
News For IPXL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 22, 2014
10:09 EDTIPXLOn The Fly: Analyst Initiation Summary
Subscribe for More Information
05:58 EDTIPXLImpax initiated with an Outperform at JMP Securities
Subscribe for More Information
October 10, 2014
10:01 EDTIPXLOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:35 EDTIPXLImpax upgraded to Buy from Hold at WallachBeth
Subscribe for More Information
06:58 EDTIPXLImpax upgraded to Buy from Hold at Needham
Subscribe for More Information
October 9, 2014
07:21 EDTIPXLImpax to host conference call
Subscribe for More Information
06:13 EDTIPXLImpax to acquire Tower Holdings, Lineage Therapeutics for $700M cash
Subscribe for More Information
06:11 EDTIPXLImpax to acquire Tower Holdings, Lineage Therapeutics for $700M cash
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use